ES2698960T3 - Compuestos de 2-aminopiridina - Google Patents
Compuestos de 2-aminopiridina Download PDFInfo
- Publication number
- ES2698960T3 ES2698960T3 ES13774069T ES13774069T ES2698960T3 ES 2698960 T3 ES2698960 T3 ES 2698960T3 ES 13774069 T ES13774069 T ES 13774069T ES 13774069 T ES13774069 T ES 13774069T ES 2698960 T3 ES2698960 T3 ES 2698960T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- pyridin
- spiro
- chloro
- decan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *N(*)c(ncc(Br)c1Cl)c1Cl Chemical compound *N(*)c(ncc(Br)c1Cl)c1Cl 0.000 description 8
- CYTYWUXQCAAJGP-WBMJQRKESA-N CN(c(cc1)c(C2)cc1-c(c(N(CC[C@@H]1C#N)C[C@@H]1O)c1Cl)cnc1N)S2(=O)=O Chemical compound CN(c(cc1)c(C2)cc1-c(c(N(CC[C@@H]1C#N)C[C@@H]1O)c1Cl)cnc1N)S2(=O)=O CYTYWUXQCAAJGP-WBMJQRKESA-N 0.000 description 2
- GYAJOZWRULCVSG-UHFFFAOYSA-N Bc(cc1)ccc1-c1c[n](CCOC2OCCCC2)nc1 Chemical compound Bc(cc1)ccc1-c1c[n](CCOC2OCCCC2)nc1 GYAJOZWRULCVSG-UHFFFAOYSA-N 0.000 description 1
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N BrCCOC1OCCCC1 Chemical compound BrCCOC1OCCCC1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 1
- UGBNWBGVSPCEGW-UHFFFAOYSA-N Brc(cc1)ccc1-c1c[n](CCOC2OCCCC2)nc1 Chemical compound Brc(cc1)ccc1-c1c[n](CCOC2OCCCC2)nc1 UGBNWBGVSPCEGW-UHFFFAOYSA-N 0.000 description 1
- RFJSLTWYYQIRMJ-UHFFFAOYSA-N Brc1ccc(C2C=NNC2)cc1 Chemical compound Brc1ccc(C2C=NNC2)cc1 RFJSLTWYYQIRMJ-UHFFFAOYSA-N 0.000 description 1
- HKDDTBGOWVUURB-UHFFFAOYSA-N CC(C)(C)OC(Nc(nc1)c(C(F)(F)F)c(Cl)c1Br)=O Chemical compound CC(C)(C)OC(Nc(nc1)c(C(F)(F)F)c(Cl)c1Br)=O HKDDTBGOWVUURB-UHFFFAOYSA-N 0.000 description 1
- JDXCSIRVKISGTF-UHFFFAOYSA-N CC(C)[n]1ncc(-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)c1 Chemical compound CC(C)[n]1ncc(-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)c1 JDXCSIRVKISGTF-UHFFFAOYSA-N 0.000 description 1
- MZJFTGUHPADNCL-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2-c2c[n](CCOC3OCCCC3)nc2)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2-c2c[n](CCOC3OCCCC3)nc2)OC1(C)C MZJFTGUHPADNCL-UHFFFAOYSA-N 0.000 description 1
- BJQRUJRFGXXKGL-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2-c2n[n](C)cc2)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2-c2n[n](C)cc2)OC1(C)C BJQRUJRFGXXKGL-UHFFFAOYSA-N 0.000 description 1
- PUGNPADVDIGSBZ-UHFFFAOYSA-N CCN(Cc1cc(Br)ccc11)S1(=O)=O Chemical compound CCN(Cc1cc(Br)ccc11)S1(=O)=O PUGNPADVDIGSBZ-UHFFFAOYSA-N 0.000 description 1
- YRSIGGJLDCPKJN-UHFFFAOYSA-N CN(c1c(C2)cccc1)S2(=O)=O Chemical compound CN(c1c(C2)cccc1)S2(=O)=O YRSIGGJLDCPKJN-UHFFFAOYSA-N 0.000 description 1
- LAMZIPQUERBHFQ-UHFFFAOYSA-N Cc1ccc(C)[n]1-c(ncc(Br)c1Cl)c1Cl Chemical compound Cc1ccc(C)[n]1-c(ncc(Br)c1Cl)c1Cl LAMZIPQUERBHFQ-UHFFFAOYSA-N 0.000 description 1
- ZDIRWPHDIWKANE-RITPCOANSA-N N#C[C@@H](CCNC1)[C@H]1O Chemical compound N#C[C@@H](CCNC1)[C@H]1O ZDIRWPHDIWKANE-RITPCOANSA-N 0.000 description 1
- LIJSPJSYJHNQGE-UHFFFAOYSA-N Nc(c(C(F)(F)F)c1Cl)ncc1Br Chemical compound Nc(c(C(F)(F)F)c1Cl)ncc1Br LIJSPJSYJHNQGE-UHFFFAOYSA-N 0.000 description 1
- XNTYVSHKTDSLBI-UHFFFAOYSA-N Nc(c(C(F)(F)F)c1N(CC2)CCC2(CCN2)C2=O)ncc1Br Chemical compound Nc(c(C(F)(F)F)c1N(CC2)CCC2(CCN2)C2=O)ncc1Br XNTYVSHKTDSLBI-UHFFFAOYSA-N 0.000 description 1
- BBYPUQDFQKZHNW-UHFFFAOYSA-N Nc(ncc(Br)c1Cl)c1Cl Chemical compound Nc(ncc(Br)c1Cl)c1Cl BBYPUQDFQKZHNW-UHFFFAOYSA-N 0.000 description 1
- TWBJZMHXXNKDPQ-UHFFFAOYSA-N Nc(ncc(Br)c1N(CC2)CCC2(c2ccccc2N2)C2=O)c1Cl Chemical compound Nc(ncc(Br)c1N(CC2)CCC2(c2ccccc2N2)C2=O)c1Cl TWBJZMHXXNKDPQ-UHFFFAOYSA-N 0.000 description 1
- MNVZZENTOQHGQD-UHFFFAOYSA-N Nc(ncc(Br)c1N(CC2)CCC22NCCNC2=O)c1Cl Chemical compound Nc(ncc(Br)c1N(CC2)CCC22NCCNC2=O)c1Cl MNVZZENTOQHGQD-UHFFFAOYSA-N 0.000 description 1
- IFJCFHFDRYJKCH-UHFFFAOYSA-O O=C1NCC2(CCCCCC2)[CH+]1 Chemical compound O=C1NCC2(CCCCCC2)[CH+]1 IFJCFHFDRYJKCH-UHFFFAOYSA-O 0.000 description 1
- JPSHGHQSNHXNFV-UHFFFAOYSA-N O=CNCCOI Chemical compound O=CNCCOI JPSHGHQSNHXNFV-UHFFFAOYSA-N 0.000 description 1
- DRTPDJJQGWIEFA-UHFFFAOYSA-N O=S1(NCc2cc(Br)ccc12)=O Chemical compound O=S1(NCc2cc(Br)ccc12)=O DRTPDJJQGWIEFA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006952 | 2012-10-08 | ||
| PCT/EP2013/002966 WO2014063778A1 (en) | 2012-10-08 | 2013-10-02 | 2-aminopyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2698960T3 true ES2698960T3 (es) | 2019-02-06 |
Family
ID=47143483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13774069T Active ES2698960T3 (es) | 2012-10-08 | 2013-10-02 | Compuestos de 2-aminopiridina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9834541B2 (enExample) |
| EP (1) | EP2912037B1 (enExample) |
| JP (1) | JP6317360B2 (enExample) |
| CN (1) | CN104755477B (enExample) |
| AR (1) | AR093143A1 (enExample) |
| AU (1) | AU2013337086B2 (enExample) |
| CA (1) | CA2889526C (enExample) |
| ES (1) | ES2698960T3 (enExample) |
| IL (1) | IL238060B (enExample) |
| WO (1) | WO2014063778A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015144290A1 (en) * | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| CN104391058B (zh) * | 2014-11-25 | 2015-12-02 | 广东东阳光药业有限公司 | 阿法替尼及其异构体的检测方法 |
| WO2018027082A1 (en) * | 2016-08-03 | 2018-02-08 | The Broad Institute, Inc. | Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity |
| EP3575297B1 (en) | 2017-01-30 | 2024-12-18 | Kyoto University | Novel compound, and method for producing regulatory t cells |
| CN111163775B (zh) | 2017-10-02 | 2023-07-11 | 勃林格殷格翰国际有限公司 | 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物 |
| WO2021126725A1 (en) * | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors |
| AR127141A1 (es) | 2021-09-27 | 2023-12-20 | Univ Kyoto | Método para producir células t |
| CN118591379A (zh) | 2021-11-24 | 2024-09-03 | 雷格细胞股份有限公司 | 用于治疗或预防t细胞相关疾病的药物组合物 |
| KR20240116751A (ko) | 2021-11-24 | 2024-07-30 | 레그셀 가부시키가이샤 | 사람 유도성 제어성 t세포 및 그 제작 방법 |
| CN114591326B (zh) * | 2022-02-28 | 2024-02-27 | 上海筛杰生物医药有限公司 | Cct-251921的中间体及其制备方法 |
| TW202345878A (zh) | 2022-03-23 | 2023-12-01 | 國立大學法人京都大學 | 控制性ｔ細胞之製造方法 |
| JPWO2024071039A1 (enExample) | 2022-09-26 | 2024-04-04 | ||
| AU2023353929A1 (en) | 2022-09-26 | 2025-05-01 | Kyoto University | T cell production method |
| TW202448492A (zh) | 2023-02-08 | 2024-12-16 | 日商雷格細胞股份有限公司 | 用於治療或預防天皰瘡的藥物組合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| BRPI0619446A2 (pt) | 2005-12-05 | 2011-10-04 | Incyte Corp | compostos de lactama, suas composições e método de modulação da atividade de 11bhsd1 |
| EP2144877A1 (en) * | 2007-04-04 | 2010-01-20 | UCB Pharma, S.A. | Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
-
2013
- 2013-10-02 JP JP2015538317A patent/JP6317360B2/ja not_active Expired - Fee Related
- 2013-10-02 US US14/437,561 patent/US9834541B2/en active Active
- 2013-10-02 EP EP13774069.2A patent/EP2912037B1/en active Active
- 2013-10-02 ES ES13774069T patent/ES2698960T3/es active Active
- 2013-10-02 CA CA2889526A patent/CA2889526C/en active Active
- 2013-10-02 WO PCT/EP2013/002966 patent/WO2014063778A1/en not_active Ceased
- 2013-10-02 CN CN201380056074.0A patent/CN104755477B/zh not_active Expired - Fee Related
- 2013-10-02 AU AU2013337086A patent/AU2013337086B2/en not_active Ceased
- 2013-10-25 AR ARP130103891A patent/AR093143A1/es unknown
-
2015
- 2015-03-31 IL IL238060A patent/IL238060B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014063778A1 (en) | 2014-05-01 |
| US20150353548A1 (en) | 2015-12-10 |
| CN104755477A (zh) | 2015-07-01 |
| JP6317360B2 (ja) | 2018-04-25 |
| AR093143A1 (es) | 2015-05-20 |
| AU2013337086A1 (en) | 2015-06-11 |
| CN104755477B (zh) | 2017-09-26 |
| CA2889526A1 (en) | 2014-05-01 |
| US9834541B2 (en) | 2017-12-05 |
| CA2889526C (en) | 2020-10-13 |
| AU2013337086B2 (en) | 2017-06-15 |
| IL238060B (en) | 2018-08-30 |
| EP2912037A1 (en) | 2015-09-02 |
| EP2912037B1 (en) | 2018-08-22 |
| JP2016500694A (ja) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2698960T3 (es) | Compuestos de 2-aminopiridina | |
| JP7268116B2 (ja) | Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| ES2720324T3 (es) | Piridil piperidinas | |
| CA3098283C (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| EA017144B1 (ru) | N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором | |
| WO2022003575A1 (en) | Her2 mutation inhibitors | |
| ES2703851T3 (es) | Indazoles | |
| AU2019395201A1 (en) | Cycloalkane-1,3-diamine derivative | |
| JP6280130B2 (ja) | キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体 |